Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Been holding for about 20 years (grape juice plant). This company has many good patients and technology. I do think it may be time for a buyout, however. Thoughts from those that have been around for a while are welcomed.
Attacking someone for asking questions? This is a place for decent conversation, not ridicule. I know plenty about the science behind this, that's why I'm invested. Worry about your own investments,not mine. Stroking? For what reason? I thought people like you were gone from this board. It's no wonder many people are hesitant to ask questions.
Thank you for clarifying.
Thanks, EI. As you can tell, the financial side is not my cup of tea. So, the SEC ref. is basically similar to a home equity loan. Would that be a fair comparison? Also, do you know how many shares are currently outstanding?
In layman's terms- could someone explain the financing portion of the this update, particularly SEC Regulation D, Rule 506 and the following paragraph....
"Any share issuance financing for this expansion is being structured primarily, but not solely, through a series of equity tranches and stock warrants. Using this method, the Company hopes to keep stock dilution to a minimum and will proceed with the interests of the shareholders in mind, including extending the timeline for expansion as necessary if equity costs are not favorable to NanoLogix."
Do we know how much dilution there will be?
Thank you in advance.
TT
Who remembers that run up over a dollar some years ago? What a ride that was! We may be in for something similar. This one is more likely to stick considering the environment of the company. It was very different at the time of the last run up.
Very exciting to be a long.
Thank you, EI.
EI, Was there a PR today (11/1), or are you referring to the update on 10/30? Could you post if there is something newer than 10/30? Thanks
Here's an interesting experiment showing bacteria mutations and antibiotic resistance.
https://m.facebook.com/story.php?story_fbid=10154469465946870&id=35695491869
NanoLogix Announces Diagnostic Customization For Major Medical Device Company
December 21, 2015 06:00 AM Eastern Standard Time
HUBBARD, Ohio (MarketWired)--NanoLogix, Inc. (NNLX), an innovator in the rapid detection, identification and determination of the antibiotic resistance and sensitivity of bacteria, is very pleased to announce that they have been contracted by one of the world’s three largest global Medical Device manufacturers to customize the NanoLogix N-Assay, a unique modified ELISA diagnostic.
NanoLogix was contacted by the company in February of 2015 and the agreement was finalized in late October with a purchase order issued in late November. NanoLogix began the initial customization of the N-Assay in December, with the client billed for one-third of the contract amount. The identity of the client and further details will remain confidential as per contract restrictions until such time as NanoLogix may be permitted to comment.
The N-Assay provides extraordinarily rapid, accurate, and sensitive detection and identification of any bacteria tested to date for which there exists an antibody, with the added capability of near-simultaneous determination of antibiotic sensitivity and resistance.
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on both rapid diagnostics and petri plates. Its products offer accelerated detection and identification of microorganisms. In addition to medical, National Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.
Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.
For more information visit: http://www.nanologix.com
This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.
Contacts
NanoLogix, Inc.
Carol Surrena, 330-534-0800
info@nanologix.com
Good news indeed! I had to chuckle at the Trump-like description of the test results. Sounds like good things moving forward into 2016!
TT
Thank you, EI
Just curious....all sales are definitely positive, but this sounds a bit low to me. What happened to the $1,000,000 deal in the Middle East? Is this part of that? Maybe I'm reading the PR wrong but is 24K in sales in one month really a chart topper? I don't know, it might be. Are other sales coming in on a monthly basis? How can we find out? Will quarterly financials be disclosed; it seems that we are going in that direction. Maybe someone could catch me up since I've been off this board for a while, not to mention that some of my posts have seemingly disappeared. Any reliable information would be appreciated. TT
The Company has recently received queries regarding the status of the N-Assay diagnostic. This email is to inform those who have interest that the N-Assay development work is in its final stages, with multiple bacteria successfully tested against as many as five separate antibiotics to determine their antibiotic sensitivity. The initial focus of the N-Assay has been primarily in the area of detecting and identifying bacteria present in the obstetrics/gynecology environment and simultaneously determining their antibiotic sensitivity. While that research has focused upon three or four bacteria and one yeast, the results of extensive testing have indicated that the N-Assay diagnostic will deliver the same exceptionally rapid detection, identification and sensitivity results for any bacteria for which an antibody exists.
In some of the queries it has become clear that there is a lack of understanding of the operations, structure and logistics of NanoLogix and how essentially a small, start-up company with sales of disruptive products (FlatPack Petri plates), develops technology with the assistance of third parties. To make it clear --- NanoLogix does not employ the researchers, MD's, or laboratory technicians in Houston who are doing the N-Assay development work. Those personnel are employed full time in their respective jobs, have families and personal lives, and are doing the development work out of their interest in what they, and we here at NanoLogix, view as an incredible technological breakthrough for a diagnostic that delivers more specific and sensitive results in literally a fraction of the time required by the BEST commercial tests available in the medical industry. NanoLogix DOES supply the antibodies and materials for the ongoing research but does not pay for the current N-Assay work being done.
That being said, it must be noted that if NanoLogix was a standard, well-financed company with millions of dollars in reserve, the work on the N-Assay and other products would have been fully funded by the company and the technology would potentially be a part of current market technology choices and ideally making a market impact as the BEST available diagnostic. As NanoLogix does not have that as a reserve, it takes longer to accomplish the same goal.
The researchers in Houston anticipate the final confirmation testing against antibiotics to be complete within a few weeks, predicated upon no problems with the quality and available quantity of vendor-supplied antibodies for the final bacteria in their test. Following that completion, the results of the research will be submitted to a peer-reviewed journal for publication. After that submittal has been completed, and prior to publication, a sensitivity confirmation study will be done by MDs and researchers who, in order to maintain objectivity in their research, were not part of the N-Assay development research. That study will be a relatively short study of potentially a month or two, and is essential for acceptance of the N-Assay for use as a diagnostic.
As a footnote, NanoLogix has been approached by an entity who has interest in having the company customize the N-Assay for particular applications. None of the work or sales will be dependent upon publication of the N-Assay primary or secondary peer-reviewed papers, if in fact this comes to fruition.
NanoLogix is pleased to share the following information:
In recent and ongoing work, researchers in the United States have confirmed the potential efficacy of NanoLogix's N-Assay as a rapid indicator for the presence of the current-threat strain of the Ebola virus, EBOV. The research demonstrates a sub-three hour result at present. Researchers are working to refine the test and reduce time-to-detection to facilitate the N-Assay's use as a Point of Care (POC) diagnostic for hemorrhagic and other viruses.
That's an interesting tool. I believe at that point they were only selling to certain institutions. It really shows how far they've come in 5 years.
Please post this link from 7 years ago.
"You are a moderator of this board. What is the role of a moderator? I ask you to explain how you view your role as a moderator. What are your responsibilities? Is a moderator's role to bring fairness in perspective and reduce the severity of extremes of comments, from all sides?"
These proposed questions are fair and should be answered.
"Much longer than you I'm certain."
Possibly, but I doubt it. If you had, then you would have known that this technolgy was in its infancy ("several")8 years ago. You couldn't buy it on the website at all. I'm sorry, but you're wrong. If you can prove me wrong, please do so, but I doubt you can.
"They've had an order page on their website for several years. I think you're mistaken."
I don't know your definition of several. They have not been selling this updated technolgy for 8 years. I don't know how long you've been following this company, but I'm quite confident that you couldn't purchase anything from their website 8 years ago.
"The company will not produce $900,000 in revenue for 2014."
If what Emerald Isle stated is true (waiting for SA FDA approval), sales could be pushed later. If this is the case, then I agree.
"Most biotechnology companies have high R&D expenses. There is nothing trivial about that unless this is the first biotech stock you've invested in and are not accustomed to the industry."
I was not referring to the expenses. I was referring to the time.
"No matter how you look at it, 8 years is not the definition of instant gratification."
Again, the point I'm trying to make is the time involved and the transformation from mostly R&D to pushing the product out. This new technology has not been "for sale" to the masses for 8 years.
"The company makes press releases available that state "an independent analyst has projected Nanologix to produce $900,000 in revenue for 2014". I didn't put that information out, Nanologix did. So when you see something like that and take note of how enthusiastic the investors are over news like that, and then you look at the actual financial statement that says $18,550 in revenue, and this kind of situation happens over and over again, you start to realize that something isn't right here."
I believe the press release was put out in January? Are those numbers supposed to be factored into the Q1 results? Now, whether you believe the 900K deal or not, it's up to you on how to move forward with the company. You can't expect this 900K to show up in Q1, heck, the agreement was signed on Jan-9-14. Was Nasaem Al-Jazira supposed to cut Bret a check for 900K at that point? That’s ridiculous. In my opinion, more of the story will become evident with the release of Q2, Q3, and Q4.
"This is the bnp patent that uses aptamers to cut down on detection time I believe. Very important to the company in my opinion."
Yes, I belive that's correct.
Actually, in all your sarcasm, you've missed the point.
I see that you're stuck on Q1 revenue. I'm quite confident that the next two quarters will be higher, and the fourth as well. Disagree? I'm sure you do...on paper. Just keep sucking those shares up at this low price.
"After nearly 8 years, $18,550 in quarterly revenue is not "good" in my opinion."
How much of this time was devoted mainly toward research and development? A significant portion, if I recall correctly. If anyone expects instant gratification (flood of revenue) from new products and technology, they are fooling themselves.
The EU patient, for example, expires in 14 years. You believe the wheels won't be spinning by then? I disagree, the wheels have begun. Time will tell. If anyone disagrees they can certainly sell their position.
Maybe you've missed this. You honestly believe that revenue isn't going to increase within the next year?
http://nanologix.com/downloads/NanoLogix-Inc-ITAC-Update-edited.pdf
NanoLogix technology has received coverage as one of a handful of potential rapid diagnostic tests for the Ebola virus in an article titled "Ebola epidemic spurs hunt for new, faster tests" by Lisa Krieger. NanoLogix was interviewed by Ms. Krieger at length regarding Ebola and its potential impact the week prior to the article's publication. The full text of the article can be viewed by following this link. 10/02/14 http://www.mercurynews.com/bay-area-news/ci_26851327 This article is the fourth article by Lisa Krieger in San Jose Mercury News over the past three weeks covering various aspects of the threat posed by the Ebola virus. Ms. Krieger is an award winning journalist and medical writer. If interested, you may find the other articles by following the links below: 10/14/14 http://www.mercurynews.com/News/ci_26728553/Ebola-scare-forces-Bay-Area-medical-facilities-to-step-up-preparedness 10/15/14 http://www.mercurynews.com/News/ci_26735650/Ebola-scare-has-Bay-Area-asking:-How-at-risk-are-we 10/28/14 http://www.mercurynews.com/News/ci_26811343/Ebolas-evolving-threat-studied-in-UCSF-lab The San Jose Mercury News and its Bay Area subsidiaries are collectively ranked as the sixth largest daily circulation newspaper in the United States.
ANTIBIOTIC RESISTANCE - EASTERN MEDITERRANEAN
*********************************************
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>
Date: Tue 28 Oct 2014
Source: The Atlantic [edited]
<http://www.theatlantic.com/health/archive/2014/10/invincible-bacteria-in-the-middle-east/381671/>
Doctors in Jordan, the region's leading destination for medical
tourism, say antibiotic-resistant infections are at an all-time high.
"We've been noticing an organism, _E. [Escherichia] coli_," [Dr.
Faris] Bakri said. "Many patients come with urinary-tract infections
with this organism," but it doesn't respond to treatment as it once
did. In 2000, _E. coli_ could be treated by the drug ceftriaxone 70 or
80 percent of the time, he estimated. Now its susceptibility is 37
percent, according to Bakri's data, which also show increasing
antibiotic resistance among other bacteria. His findings, based on the
hospital's patients, parallel national trends. "It's all over the
country. Everyone's complaining of this phenomenon," he said.
In this new nightmarish world, patients with moderate infections are
admitted to hospitals "for very expensive IV antibiotics," Bakri said,
because "they just won't respond to oral antibiotics." For virulent
infections, even fewer antibiotics are effective, and treatment is
more complex. And as health systems deteriorate in surrounding
countries, war-injured patients with complicated wounds are flocking
to Jordan, the Middle East's top destination for medical tourism, for
treatment, bringing fierce infections with them.
"We think that the Middle East is one of the hotspots globally for
antibiotic resistance," said Richard Murphy, an infectious-disease
specialist with Doctors Without Borders. We spoke in September [2014]
during a 2-day conference in Amman organized by DWB [Doctors Without
Borders] to jumpstart regional discussion and action on antibiotic
resistance. The global medical NGO works all over the world, but it
encounters notably high rates of resistance in the Middle East.
In this perfect storm of relaxed policy and lack of awareness, the
abuse of antibiotics is almost a baseline in healthcare.
In Amman, DWB runs a reconstructive surgical project, which tackles
complex cases like severe burns or bone infections. Since 2006, the
project has treated 3000 patients from places like Gaza, Yemen, Libya,
Syria, and Iraq. DWB's analysis found that drug-resistant bacteria
caused 69 percent of all infections in Syrian patients and were
present in 55 percent of Iraqi patients with bone infections. The
project's surgical coordinator, Dr. Rashid Fakhri, estimated that
overall, 60 to 65 percent of bacteria among the project's patients
carry some form of resistance.
To kill these infections, "the antibiotic we use is the last one used
in Europe," said Marc Schakal, DWB's head of mission for Jordan and
Iraq. That antibiotic is imipenem, a broad-spectrum intravenous
medication. Although it's usually a last resort, it's the drug DWB
uses most frequently in Amman because 1st-line antibiotics aren't as
effective. A full 6-week course of imipenem costs USD 2600 to USD
3000.
>From 1970 to 1995, Arab countries went through "an impressive
construction program of public hospitals and health centers,"
according to a 2012 review of the area's health services. Healthcare
became more readily available in many of these countries, except ones
in conflict, and several, including Jordan, "developed world-class
factories for the manufacture of generic medications" for export and
domestic use. The report highlighted "the inappropriate usage of
antibiotics," which, The Lancet has written, "has contributed to the
development of microbial resistance in the region." As health systems
and access to medical drugs flourished, however, awareness about their
proper use among both health professionals and patients lagged.
"People here take antibiotics for knee pain, for runny noses," Bakri
said. "Doctors are under a lot of pressure from the patient to
prescribe antibiotics, because if the patient doesn't receive
antibiotics, he will not go back to the doctor." Dr. Najwa Jarour,
head of the infection-control department at Jordan's Ministry of
Health, added, "Even doctors write prescriptions for antibiotics
without knowing if [an infection] is viral or bacterial," and patients
often don't complete prescribed courses of antibiotics, stopping as
soon as they feel better.
Even without a prescription, a person can walk into a pharmacy in
Jordan, present symptoms or a self-diagnosis -- "Good afternoon, I
believe I have a urinary-tract infection" -- and the pharmacist will
most likely hand over some affordable blister packs of antibiotics. In
this perfect storm of relaxed policy, lack of awareness, and doctors
and pharmacists worried about making money, the lax dispensation of
antibiotics and their consequent abuse is almost a baseline in
healthcare.
The other major factor is war. Recent years have witnessed substantial
violence in the Middle East -- 2014 alone includes the ongoing war in
Syria, renewed fighting (again) in Iraq, and Israel's war with Hamas,
plus continuing conflicts in Yemen, Libya, and elsewhere. Better
initial treatment is not always feasible in conflict zones. In Syria,
60 percent of hospitals have been damaged or destroyed since the start
of the war.
"When health systems are fragile and patients don't get good initial
treatment for their injuries, they frequently end up living with a
chronic injury," DWB's Murphy explained. These injuries are
susceptible to infection, which could be avoided if better initial
treatment were available, he said. DWB's Iraqi patients in Amman have
undergone an average of 4 previous operations, with 19 months on
average between injury and DWB admission.
Even with ... Bakri's internal data, and DWB's analysis of patients
bearing extraordinarily complex wounds, it's hard to glean precisely
the impact on Jordan from antibiotic resistance. "You've got no idea
of the levels of resistance coming in," said Tim Walsh, a medical
microbiology and antimicrobial resistance professor at Cardiff
University in Wales, while in Jordan, data on resistance are "almost
nonexistent." Indeed, Ministry of Health surveillance of resistance is
limited to select units in 4 public hospitals, though it has revealed
high levels of bacterial resistance to both 1st-line and last-resort
antibiotics.
Bakri said the university hospital had not conducted cost-impact
studies, while Jarour, the health ministry official, couldn't say what
antibiotic resistance might cost Jordan in the long run. But both were
certain they'd see higher healthcare costs, worsening morbidity rates,
and above all, more deaths. As Bakri stated frankly, "It's going to be
a disaster."
[Byline: Elizabeth Whitman]
--
Communicated by:
ProMED-mail from HealthMap Alerts
<promed@promedmail.org>
[Antimicrobial resistance is a worldwide problem, affects many types
of pathogens, has appeared in both healthcare and more recently in
community-acquired infections, and has major clinical and economic
consequences. A recent report by WHO revealed "extensive antibiotic
resistance across the WHO Eastern Mediterranean Region", which
includes the countries mentioned in the article above (Jordan, Syria,
Iraq, and Lybia)
(<http://www.who.int/mediacentre/news/releases/2014/amr-report/en/>
and ProMED-mail post Antibiotic resistance - worldwide: WHO
20140501.2442194).
Similar to the article above, the WHO report goes on to say that in
the WHO Eastern Mediterranean Region, "In particular, there are high
levels of _E. coli_ resistance to 3rd generation cephalosporins and
fluoroquinolones -- 2 important and commonly used types of
antibacterial medicine. Resistance to 3rd generation cephalosporins in
_K[lebsiella] pneumoniae_ is also high and widespread.... The report
reveals major gaps in tracking of antibiotic resistance in the
Region."
Most likely the article above is referring to extended-spectrum
beta-lactamase (ESBL)-producing _E. coli_. ESBLs hydrolyze penicillins
and cephalosporins, including the extended-spectrum cephalosporins
with an oxyimino side chain (cefotaxime, ceftriaxone, ceftazidime, and
cefepime), as well as the oxyimino-monobactam aztreonam. Most ESBLs
are inhibited to some extent by beta-lactamase inhibitors such as
clavulanate, sulbactam, or tazobactam in vitro; but the clinical
effectiveness of beta-lactam/beta-lactamase inhibitor combinations
cannot be relied on consistently for therapy.
Because the genes that encode ESBLs are located on plasmids, the
ESBL-encoding genes are easily transferable to other bacteria of the
same or even different species. These plasmids also carry genes
conferring resistance to several non-beta-lactam antibiotics.
Consequently, ESBL-producing isolates are commonly resistant to many
classes of antibiotics, most frequently aminoglycosides,
fluoroquinolones, tetracyclines, chloramphenicol, and
sulfamethoxazole-trimethoprim. Infections caused by these multiple
drug-resistant organisms are most reliably treated with a carbapenem
antibiotic, such as imipenem, meropenem, ertapenem, and doripenem.
There are multiple types of ESBLs, such as, TEM, SHV, CTX-M, OXA, each
with multiple subtypes. One type, CTX-M-15 is currently the most
widespread type in _E. coli_ in the UK and is reported to be widely
prevalent in the community (Woodford N, Ward ME, Kaufmann ME, et al:
Community and hospital spread of _Escherichia coli_ producing CTX-M
extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother
2004; 54(4): 735-43. Available at
<http://jac.oxfordjournals.org/content/54/4/735.full>.)
The use of carbapenems, the antibiotics of last resort to treat
multidrug-resistant Enterobacteriaceae, has now become compromised by
the spread of carbapenemases (e.g., KPCs and NDMs), beta-lactamases
that destroy the carbapenem antibiotics, which leaves only toxic or
otherwise suboptimal antibiotics to treat patients infected by
carbapenemase-producing Enterobacteriaceae.
A map showing the countries in the WHO Middle Eastern Region is
available at: <http://www.who.int/about/regions/emro/en/>. - Mod.ML]
[See Also:
Gram-negative bacilli, MDR - Uruguay: (FD) KPC, nosocomial, fatal
20140928.2812844
NDM-4 carrying Enterobacteriaceae - India: (UP) hospital sewage
20140905.2749919
Enterobacteriaceae, carbapenem resistant - USA: southeastern community
hospitals 20140719.2621485
Antibiotic resistance - new metallo-beta-lactamase (NDM-1) inhibitor
20140627.2568937
Antibiotic resistance - India 20140505.2449567
Antibiotic resistance - worldwide: WHO 20140501.2442194
NDM-1 carrying Enterobacteriaceae - China: (HK) 20140501.2442036
Enterobacteriaceae, carbapenem resistant - France: ex India
20140412.2399151
NDM carrying Gram-negative bacilli - Americas: Update
20140309.2322398
Enterobacteriaceae, carbapenem resistant - UK: (England) increased
incidence 20140308.2321781
NDM-1 carrying E. coli - USA: (IL) ERCP 20140104.2151607
2013
----
Antimicrobial resistance - Netherlands ex Egypt: family
2011
----
Antibiotic resistance, E. coli - UK (02): (Wales) ESBL 20111128.3471
Antibiotic resistance, E. coli - UK: (Wales) ESBL 20111126.3454
2007
----
E. coli, ESBL - UK 2000
Update
This update is related to the Press Release issued by NanoLogix 14 October 2014 At a minimum, the press release has been covered with stories in the Washington Post Innovation blog, The Warren Tribune Chronicle, Warren, Ohio; The YoungstownCBS/Fox/ABC/NBC Youngstown, Ohio affiliated television stations; NBC/Pittsburgh, Fox/Tampa television. As a result, NanoLogix N-Assay (V) is currently being evaluated by pharmaceutical companies for use as a simple rapid diagnostic tool for viruses for use in remote locations in close proximity to outbreak events. Nanologix this week signed two Mutual Confidentiality Agreements with US corporations interested in their technology. Given the key word "Confidentiality", further information will be released when and if dictated by events.
I don't think we can do viruses with our product, unfortunately.
Recent Update
NanoLogix received notification at the end of July of results for two time and temperature related tests that have been performed by a renowned independent third-party lab.
In the first test, NanoLogix Tryptic Soy Agar (TSA) petri plates packed in the company's proprietary FlatPacks reached the 2-year point for room-temperature (RT) storage. The final test results for culturing of bacillus anthracis Ames (Anthrax) on the two-year-old plates were superior to the results obtained with competitor's one-week-old TSA plates, with NanoLogix's TSA plates performing as the equivalent to freshly poured plates. NanoLogix has elected to end the study, as the supply of FlatPacks that were furnished to the third-party lab two years ago predicated upon an initial four- month test for the DOD has been exhausted. The company recently completed its own testing of FlatPack packaged TSA petri plates stored for 3 years in cold storage with E-coli 0157 H7 as the test bacteria and observed results similar to those of the third-party lab 2 year RT test for Anthrax.
In a second test that was begun in June for determination of the stability of three different types of FlatPack-packaged agars under conditions conforming to MilSpec requirements for "Desert Hot" (to 60+ degrees Centigrade), the Flatpacks provided excellent agar protection and stability in simulated total power loss for periods of 24 hours, 7 days, and 30+ days, with culture results at all periods comparable to refrigerated and room temperature stored FlatPacks. The tests of NanoLogix FlatPacked plates were compared to plates furnished by competitors, with the competitors' plates performing adequately after 24 hours, but being completely desiccated and unusable by the 7-day point.
A peer reviewed paper will be published either in 2014 or early 2015 detailing the actual studies with results and control data.
The staff at NanoLogix are elated over the three sets of test results, as they demonstrate the unique product durability that NanoLogix is able to furnish to their clients.
NNLX Email - Patent Update
The European Patent Office has informed our London and US Patent Law firms that our European application for the BNP has been granted as a European Patent under the European Patent Convention. The 38 member states where this patent applies are:Germany, France, Luxembourg, Netherlands, Switzerland, United Kingdom, Sweden, Italy, Austria, Liechtenstein, Greece, Spain, Denmark, Monaco, Portugal, Ireland, Finland, Cyprus, Turkey, Bulgaria, Czech Republic, Estonia, Slovakia, Slovenia, Hungary, Romania, Poland, Iceland, Lithuania, Latvia, Malta, Croatia, Norway, Former Yugoslav Republic of Macedonia, San Marino, Albania, and Serbia. With the EU Patent grant, NanoLogix is electing to file for national patent issuance in the majority of the covered countries with some exceptions. This BNP patent grant joins the NanoLogix portfolio of patents for the BNP granted in Japan and Russia, and when each member state patent is issued to NanoLogix will dramatically increase the number of granted patents in our portfolio.
FYI-
ANTIMICROBIAL RESISTANCE - INDIA
********************************A ProMED-mail post<http://www.promedmail.org>ProMED-mail is a program of theInternational Society for Infectious Diseases<http://www.isid.org> Date: Thu 1 May 2014Source: The Times of India, Mumbai/Times News Network (TNN) [edited]<http://timesofindia.indiatimes.com/city/mumbai/Drug-resistance-now-routine-even-in-typhoid-doctors-want-antibiotic-policy/articleshow/34495091.cms?> While an antibiotics policy is on the anvil for the 3 major municipalhospitals in Mumbai, the majority of private hospitals, nursing homes,and standalone consultants there continue to prescribe antibioticsarbitrarily. Studies show the rate of resistance to antibiotics hasquadrupled from 5 percent to 20 percent in civic hospitals. What therate is in private hospitals remains anyone's guess. A WHO report released on Wednesday [30 Apr 2014] warned that the worldis darting towards a post-antibiotic era, where common infections andsurgeries can turn fatal because of ineffective drugs. Unsurprisingly,the report has set alarm bells ringing. It says that many of the 114nations that contributed to the study lack measures to curb drugresistance. India may be among these since it is still designing anational policy whose implementation may take years. Given the prevalence of drug resistance, years may be too long a wait. Recently, a Nalasopara woman suffered multiple complications,necessitating 2-month hospitalization, after being infected with methicillin-resistant _Staphylococcus aureus_, a hospital-acquired infection that can become life-threatening. A child birth at Cama andAlbless Hospital had become near-fatal for the 33-year-old mother. Inanother case, a man spent about a month at PD Hinduja Hospital after contracting pneumonia and developing resistance to the medication. "Resistance to the best of antibiotics is turning routine. Not justfrom hospital, people are getting resistant bugs directly from thecommunity. We see resistance in ailments like gastroenteritis,pneumonia, typhoid and malaria," said Dr Khushrav Bhajan, intensivist,Hinduja Hospital. Many like Dr Bhajan feel the abuse of antibiotics begins with general physicians, continues with hospitals and nursing homes operating without antibiotic stewardship, and extends to the local chemist whodispenses drugs without valid prescription. "Barring a few majorhospitals, nobody has a policy to regulate antibiotic use," said DrLalit Kapoor of the Association of Medical Consultants. "Worse are thecombinations of drugs used." Specialists concede that prescription ofmultiple antibiotics by doctors is sometimes at the insistence ofpatients wanting to recover quickly. Appropriate drug combinations hold the key to beat resistance, said DrRohini Kelkar, head of Tata Memorial Hospital's microbiologydepartment. "It is preferred to a single antibiotic regimen. Theproblem is that clinicians treat the bacteria, not the infection." [Byline: Sumitra Deb Roy] --Communicated by:ProMED-mail from HealthMap Alerts<promed@promedmail.org> [This news report above refers to a recent WHO publication (1) and itssummary (2), which ProMED-mail posted on 1 May 2014 (Antibioticresistance - worldwide: WHO 20140501.2442194). 1. Antimicrobial resistance: global report on surveillance -- 2014.Full report:<http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1>.2. Antimicrobial resistance: global report on surveillance -- 2014Summary:<http://apps.who.int/iris/bitstream/10665/112647/1/WHO_HSE_PED_AIP_2014.2_eng.pdf?ua=1>. In this report, WHO cited increasing antibiotic resistance in the WHOSouth-East Asia Region, which is home to a quarter of the world'spopulation, specifically mentioning high levels of Enterobacteriaceaeresistance to 3rd generation cephalosporins and fluoroquinolones andhigh levels of _S. aureus_ infections resistant to methicillin. Butthe problem of antibiotic resistant pathogens in this region is muchmore extensive. It includes, for example, multidrug resistant_Mycobacterium tuberculosis_, _Salmonella typhi_ , _Campylobacter_,and _Vibrio cholerae_, carbapenemase-producing Enterobacteriaceae, anddrug-resistant malaria parasites, as has been reported in priorProMED-mail posts listed below. Antibiotic resistance is not restricted just to hospitals in India,but is circulating widely in the community, and its causes are notrestricted just to overuse of antibiotics by physicians or pharmacistswho dispense antibiotics without valid prescriptions. Its causes arecomplex and will require wide-ranging efforts to control. India is a large producer of the world's supply of genericantibiotics. In fact, India's pharmaceutical industry supplies 40percent of over-the-counter and generic prescription drugs consumed inthe United States, and the US scrutiny of Indian drug plants last year(2013) led to a flood of new penalties, including half of the warningletters the agency issued last year to drug makers(<http://www.nytimes.com/2014/02/15/world/asia/medicines-made-in-india-set-off-safety-worries.html>).This level of antibiotic production in India, however, poses risks tohuman health by exposing people and wildlife to the drugs and bycreating local environmental conditions for pathogens to developantibiotic resistance. Antibiotic resistant organisms and their mobilegenes that encode resistance to antibiotics can be incorporated in thehuman microbiome and then spread in an environment of unsanitarydisposal of human fecal waste and a contaminated water supply. A study found high levels of antibiotics downstream from a waste-watertreatment plant that received effluent water from 90 Indian drugproduction facilities near Hyderabad, India -- much higher levels thanlevels measured in waters that receive sewage effluent in the USA. Inaddition, high levels of antibiotics were found both in well waterthat was used for drinking by local villagers and in lakes that do nottake in wastewater from the sewage plant, suggesting that drugcontamination of surface, ground, and drinking water was moregeneralized (Fick J, Soederstroem H, Lindberg RH, et al: Contaminationof surface, ground, and drinking water from pharmaceutical production.Environ Toxicol Chem. 2009 Dec; 28(12): 2522-7. doi: 10.1897/09-073.1;available at<http://onlinelibrary.wiley.com/doi/10.1897/09-073.1/full>). A subsequent study of DNA sampled from river sediment downstream fromthe Indian treatment plants identified a high prevalence of genes thatencode resistance for multiple classes of antibiotics and geneticelements (including integrons, transposons, and plasmids) thattransfer resistance genes from one bacterium to another. The resultssuggested that environmental releases of effluent contaminated withantibiotics promote resistance genes and genetic elements for theirmobility. (Kristiansson E, Fick J, Janzon A, et al: Pyrosequencing ofantibiotic-contaminated river sediments reveals high levels ofresistance and gene transfer elements. PLoS One. 2011 Feb 16; 6(2):e17038. doi: 10.1371/journal.pone.0017038; available at<http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0017038>). Extended-spectrum beta-lactamases (ESBLs) are plasmid-encoded enzymesthat mediate resistance to extended-spectrum (3rd generation)cephalosporin antibiotics as well as many other beta-lactamantibiotics, including penicillins, cephalosporins, and the monobactamaztreonam. In a study of 3004 Gram negative bacilli collected fromintra-abdominal infections in the Asia-Pacific region during 2007,ESBL rates in Enterobacteriaceae were highest in India (about 70percent or more were ESBL-producers); additionally, in India, thefrequency of ESBL-producers in the community-acquired-intra-abdominalinfections of 79.0 percent was virtually identical to that inhospital-acquired infections (78.9 percent)(<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715591/>). The veryhigh rates of ESBL-positive strains were seen over the entire countryand were not restricted to any single city or region. Antibiotic-resistance in bacteria has been found to be about 60 timesgreater in May and June than other times of the year in water sampledfrom the Upper Ganges River in the foothills of the Himalayas, one ofthe most pristine locations in Asia, and linked to the annual humanpilgrimages to the region, when hundreds of thousands of people visitsacred sites(<http://www.ncl.ac.uk/press.office/press.release/item/water-samples-from-the-upper-ganges-river-shed-light-on-the-spread-of-potential-superbugs>). New Delhi metallo-beta-lactamase-1 (NDM-1) is a plasmid-encoded enzymethat mediates resistance to almost all beta-lactam antibiotics. Thegene encoding NDM-1 has been found in 51 of 171 samples of pools ofwater in streets or rivulets and 2 of 50 samples of public tap watercollected from sites within a 12 km [7.5 mi] radius of central NewDelhi (<http://www.ncbi.nlm.nih.gov/pubmed/21478057>). Acquisition of antibiotic resistant bacteria is not only a problem forIndians living in the country, but also for tourists. A study foundthat the risk of acquisition of an ESBL-producing _Escherichia coli_was highest for travelers visiting India -- 88 percent of healthySwedish volunteers traveling to India who were negative pre-travel,were colonized with ESBL-producing _E. coli_ after the trip to India(<http://aac.asm.org/content/54/9/3564.full>). Travel to otherdestinations was associated with the following rates of post-travelESBL colonization: 32 percent for Asia (India excluded), 29 percentfor the Middle East, 13 percent for Southern Europe, and 0 to 4percent for other parts of the world. Control of antibiotic resistance in India presents an immensechallenge. These examples suggest that control in India will requirenot only regulation of antibiotic use and infection control inhealthcare facilities, but also require much improved level ofenvironmental sanitation, quality control and testing of drinkingwater, and also improved wastewater management in one of the world'slargest centers for antibiotic production. - Mod.ML A HealthMap/ProMED-mail map can be accessed at:<http://healthmap.org/promed/p/482>.] [See Also:Antibiotic resistance - worldwide: WHO 20140501.2442194NDM-1 carrying Enterobacteriaceae - China: (HK) 20140501.2442036Enterobacteriaceae, carbapenem resistant - France: ex India20140412.23991512013----Salmonellosis, st. Paratyphi A - Japan: ex India, multidrug resistance20131117.2057055Bacterioides fragilis - USA: (WA) ex India susp, multidrug resistance20130830.1912302Campylobacteriosis - India, Canada: drug resistance 20130717.18279162012----NDM-1 carrying Vibrio cholerae - India 20120801.1224333Typhoid fever update 2012 (09) 20120420.1107274NDM-1 carrying Enterobacteriaceae - Ireland: 1st rep, ex India20120217.1044861Tuberculosis, TDR - India (04): (MH) fatal 20120119.1015543Tuberculosis, TDR - India: (MH, KA) 20120110.10056632011----Antibiotic resistance, Salmonella typhi - India (02): (Mumbai)fluoroquinolones 20111105.3296Antibiotic resistance, Salmonella typhi - India: (Mumbai)fluoroquinolones 20111031.3235NDM-1 carrying Enterobacteriaceae - India (02): nosocomial infections20111006.3009NDM-1 carrying Enterobacteriaceae - India: (New Delhi) water supply20110411.11452010----NDM-1 carrying Enterobacteriaceae (04): Taiwan ex India 20101005.3604NDM-1 carrying Enterobacteriaceae - worldwide ex India, Pakistan (02)20100914.3325NDM-1 carrying Enterobacteriaceae - worldwide ex India, Pakistan20100817.2853NDM-1 carrying Enterobacteriaceae - N America, UK ex India20100815.28122009----Malaria, artemisinin resistance - SE Asia (02) 20091230.4386].................................................sb/ml/mj/jw*##########################################################*************************************************************ProMED-mail makes every effort to verify the reports thatare posted, but the accuracy and completeness of theinformation, and of any statements or opinions basedthereon, are not guaranteed. The reader assumes all risks inusing information posted or archived by ProMED-mail. ISIDand its associated service providers shall not be heldresponsible for errors or omissions or held liable for anydamages incurred as a result of use or reliance upon postedor archived material.************************************************************Donate to ProMED-mail. Details available at:<http://www.isid.org/donate/>************************************************************Visit ProMED-mail's web site at
NanoLogix will exhibit its technology at the annual Food Safety Summit to be held April 8-10, 2014 in Baltimore, Maryland at the Baltimore Convention Center. This is the fifth appearance for NanoLogix at the annual event. The Company will display their technology at Booth 625. On display will be standard Petri and BNP sandwiched-membrane culture technologies packed in revolutionary extended-life Flatpacks, in addition to a new BNP variant currently in use by an Ohio regional supermarket chain. That company discovered NanoLogix and their rapid diagnostic technologies at the 2013 Food Safety Summit. Additional information on the event may be found by following this link: http://www.foodsafetysummit.com/
Thank you.
MODS: Please delete my last post. Thank you
WDB1, I agree with your projections for 2014. Absolutely plausible.
I'm saying this is a conservative projection FOR THIS PARTICULAR CONTRACT as stated in the PR. My point is that it seems silly to think that this the only source of revenue, or will be the only source of revenue in 2014.